Kevin Laliberte, Senior VP, Product Development at Dova Pharmaceuticals, Inc. (DOVA), bought 6,200 shares at $17.00 ($105K) on 2017-07-05, disclosed to the SEC on 2017-07-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| DOVA | SELL | 2019-08-01 | $22K | — | Filing → |
| DOVA | SELL | 2019-07-02 | $17K | — | Filing → |